Bringing Discoveries to Commercialization
Directions to the Entrepreneur Investor Forum_Oct 16th

Directions to the Entrepreneur Investor Forum_Oct 16th

Thursday, September 27, 2018

Entrepreneur-Investor Forum detailed agenda

Thursday, September 27, 2018


Click for more details…….

Thursday, September 27, 2018

The First Academic Entrepreneur-Investor Forum

Indiana Center for Biomedical Innovation (ICBI)  is hosting the “Entrepreneur-Investor Forum” on October 16th, 2018. The goal of the event is to bring together the key organizations involved in life sciences entrepreneurial ecosystem in Indianapolis and catalyze collaboration to promote commercialization of life science technologies. The event will be organized in partnership with Indiana-CTSI, Indiana Biosciences Research Institute (IBRI) and Indiana University-Health (IU-Health). Please click here for the detailed agenda for the forum.



HB Therapeutics Joins ICBI, Received NIH/NCI SBIR Phage I Grant

Thursday, September 27, 2018

ICBI welcomes HB Therapeutic, Inc., which just received the NIH/NCI SBIR phase I grant of $300,000 for development of the company first small molecule degraders of small ubiquitin-like modifier-1 protein (SUMO1) as new anticancer drugs.

Founded by Dr. Bellail and Dr. Hao in 2015, HB Therapeutics is a biotech company for discovery and development of small molecule degraders inducing ubiquitination and degradation of oncoproteins. The first degraders of small ubiquitin-like modifier (SUMO1) protein are now in preclinical stage and several small molecule degraders of other oncoproteins are in the company pipeline for development of new classes of anticancer drugs.

ICBI Company Vascugen Licenses Stem Cell Technology for Blood Vessel Regeneration, Raises $635K

Thursday, September 27, 2018

INDIANAPOLIS, May 1, 2018 — Vascugen Inc. today announced that it has licensed a suite of intellectual property developed at the Indiana University (IU) School of Medicine related to blood vessel formation from adult stem cells. The regenerative medicine company is focused on finding therapies to repair tissues damaged by reduced blood flow due to disease or injury.

Additionally, Vascugen has also raised around $635 thousand dollars of external funds.

Read more…

ICBI Company Scioto Biosciences Closes $1.8M in Series A Financing, Receives Grants to Support Launch of New Microbiome Platform Technology

Thursday, September 27, 2018

Scioto Biosciences, a preclinical stage company developing innovative therapies to transform the delivery of microbiome therapeutics, today announced it has closed on $1.8M in Series A financing to support the launch of its new microbiome platform technology.

The funding represents a first-time interstate collaboration between two Indiana-based investors, BioCrossroads and Elevate Ventures, together with Ohio-based Rev1 Ventures, and follows a $330,000 Small Business Technology Transfer grant from the National Institute of Health (NIH) along with a $50,000 match from the State of Indiana.

Read more…

Technology Forum by Meso Scale Discovery

Thursday, September 27, 2018

Technology seminar by Meso Scale Discovery (MSD), January 17th, 12:30-1:30 pm at the Indiana Center for Biomedical Innovation (ICBI).

MSD provides singleplex and multiplexed assays for neurodegenerative, metabolic inflammation, oncology, toxicology, cell signaling and a broad range of other disease-focused biomarkers. It is also an open platform with necessary tools to help develop assays for your drug discovery needs. Read Now




Invention to Startup Forum at ICBI: February 23rd at 12:30pm

Thursday, September 27, 2018

Invention to Startup forum presentation by Femtera Laboratories LLC (ICBI startup company), developing cancer biomarkers using metabolomics.

Title of the Talk: Metabolomics: on the way towards practical clinical application

Friday, February 23rd, at 12:30pm at the Indiana Center for Biomedical Innovation (ICBI).

Entrepreneurial Accelerator Branches to Indiana_7 wks_ accelerator _program

Thursday, September 27, 2018

gener8tor a nationally ranked accelerator has branched to Indiana, plans to offer seven-week program to five Indianapolis startups at the end of April.

gBETA program is free, seven-week accelerator for early-stage companies. Each program is capped at five teams, and requires no fees and no equity.


The program dates are April 26th – June 15, 2018 and applications are due April 6th.

Check out our website to learn more, sign up for office hours, or apply:


Participating Companies Receive:

  • Access to a community of entrepreneurs including their fellow cohort members, as well as gener8tor and gBETA alumni.
  • A formal relationship with at least 2-3 mentors with relevant expertise.
  • Introductions to the gener8tor network of successful entrepreneurs, angel investors, venture capitalists and technologists.
  • Individualized coaching and mentorship from the experienced gener8tor team.
  • Office space.
  • $1M+ in deals and perks from vendors like SoftLayer, Rackspace, Amazon, PayPal, Zendesk and Microsoft.

Allinaire Therapeutics Receives Significant Funding

Thursday, September 27, 2018

Allinaire Therapeutics, a respiratory therapeutics start-up launched by BioMotiv, has recently received new investments from BioCrossroads’ Indiana Seed Fund and Indiana University’s Innovate Indiana Fund. The Funding will advance the development of therapeutics for the treatment of chronic obstructive pulmonary disorder (COPD) and other respiratory diseases. Read Now